Publications: Our research

Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants

Immunogenicity of a fourth Homologous dose of NVX-CoV2373

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages

With established safe and effective use, protein vaccines offer another choice against COVID-19

Safety and immunogenicity of a booster dose of Novavax COVID-19 vaccine, Adjuvanted (NVX-CoV2373) in adults from the PREVENT-19 trial in the United States

Update on NovavaxInvestigational Influenza vaccine and COVID-19-Influenza Combination Vaccine development

Paving the way for protein: Novavax’s COVID-19 vaccine as a booster and variant-adapted

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Immune Correlates of Protection from Filovirus Efficacy Studies in Non-Human Primates

Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings